Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/S2666-7568(22)00247-1 | ||||
| Año | 2023 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background: The triglyceride glucose (TyG) index is an easily accessible surrogate marker of insulin resistance, an important pathway in the development of type 2 diabetes and cardiovascular diseases. However, the association of the TyG index with cardiovascular diseases and mortality has mainly been investigated in Asia, with few data available from other regions of the world. We assessed the association of insulin resistance (as determined by the TyG index) with mortality and cardiovascular diseases in individuals from five continents at different levels of economic development, living in urban or rural areas. We also examined whether the associations differed according to the country's economical development. Methods: We used the TyG index as a surrogate measure for insulin resistance. Fasting triglycerides and fasting plasma glucose were measured at the baseline visit in 141 243 individuals aged 35–70 years from 22 countries in the Prospective Urban Rural Epidemiology (PURE) study. The TyG index was calculated as Ln (fasting triglycerides [mg/dL] x fasting plasma glucose [mg/dL]/2). We calculated hazard ratios (HRs) using a multivariable Cox frailty model with random effects to test the associations between the TyG index and risk of cardiovascular diseases and mortality. The primary outcome of this analysis was the composite of mortality or major cardiovascular events (defined as death from cardiovascular causes, and non-fatal myocardial infarction, or stroke). Secondary outcomes were non-cardiovascular mortality, cardiovascular mortality, all myocardial infarctions, stroke, and incident diabetes. We also did subgroup analyses to examine the magnitude of associations between insulin resistance (ie, the TyG index) and outcome events according to the income level of the countries. Findings: During a median follow-up of 13·2 years (IQR 11·9–14·6), we recorded 6345 composite cardiovascular diseases events, 2030 cardiovascular deaths, 3038 cases of myocardial infarction, 3291 cases of stroke, and 5191 incident cases of type 2 diabetes. After adjusting for all other variables, the risk of developing cardiovascular diseases increased across tertiles of the baseline TyG index. Compared with the lowest tertile of the TyG index, the highest tertile (tertile 3) was associated with a greater incidence of the composite outcome (HR 1·21; 95% CI 1·13–1·30), myocardial infarction (1·24; 1·12–1·38), stroke (1·16; 1·05–1·28), and incident type 2 diabetes (1·99; 1·82–2·16). No significant association of the TyG index was seen with non-cardiovascular mortality. In low-income countries (LICs) and middle-income countries (MICs), the highest tertile of the TyG index was associated with increased hazards for the composite outcome (LICs: HR 1·31; 95% CI 1·12–1·54; MICs: 1·20; 1·11–1·31; pinteraction=0·01), cardiovascular mortality (LICs: 1·44; 1·15–1·80; pinteraction=0·01), myocardial infarction (LICs: 1·29; 1·06–1·56; MICs: 1·26; 1·10–1·45; pinteraction=0·08), stroke (LICs: 1·35; 1·02–1·78; MICs: 1·17; 1·05–1·30; pinteraction=0·19), and incident diabetes (LICs: 1·64; 1·38–1·94; MICs: 2·68; 2·40–2·99; pinteraction <0·0001). In contrast, in high-income countries, higher TyG index tertiles were only associated with an increased hazard of incident diabetes (2·95; 2·25–3·87; pinteraction <0·0001), but not of cardiovascular diseases or mortality. Interpretation: The TyG index is significantly associated with future cardiovascular mortality, myocardial infarction, stroke, and type 2 diabetes, suggesting that insulin resistance plays a promoting role in the pathogenesis of cardiovascular and metabolic diseases. Potentially, the association between the TyG index and the higher risk of cardiovascular diseases and type 2 diabetes in LICs and MICs might be explained by an increased vulnerability of these populations to the presence of insulin resistance. Funding: Full funding sources are listed at the end of the paper (see Acknowledgments).
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Lopez-Jaramillo, Patricio | Hombre |
Universidad de Santander - Colombia
Univ Santander - Colombia |
| 2 | Gomez-Arbelaez, Diego | Hombre |
Universidad de Santander - Colombia
Univ Santander - Colombia |
| 3 | Martinez-Bello, Daniel | Hombre |
Universidad de Santander - Colombia
Univ Santander - Colombia |
| 4 | Hori, M. | Hombre |
Philippine General Hospital - Filipinas
Philippine Gen Hosp - Filipinas |
| 5 | AlHabib, Khalid F. | Hombre |
King Saud University - Arabia Saudí
King Saud Univ - Arabia Saudí |
| 6 | Avezum, Álvaro | Hombre |
Hospital Alemao Oswaldo Cruz - Brasil
Hosp Alemao Oswaldo Cruz - Brasil |
| 7 | Barbarash, Olga L. | Mujer |
Kuzbass Cardiology Center SB RAS - Rusia
Fed State Budgetary Inst Res Inst Complex Issues - Rusia |
| 8 | Chifamba, Jephat | - |
University of Zimbabwe - Zimbabue
Univ Zimbabwe - Zimbabue |
| 9 | Diaz, Maria Luz | Mujer |
Estudios Clínicos Latinoamérica, Argentina - Argentina
Estudios Clin Latinoamer - Argentina Inst Cardiovasc Rosario - Argentina |
| 10 | Gulec, Sadi | Hombre |
Ankara Üniversitesi - Turquía
Ankara Univ - Turquía |
| 11 | Ismail, Noorhassim | Mujer |
Faculty of Medicine, UKM - Malasia
Univ Kebangsaan Malaysia - Malasia |
| 12 | Iqbal, Romaina | Mujer |
The Aga Khan University - Pakistán
Aga Khan Univ - Pakistán |
| 13 | Kelishadi, R. | Mujer |
Isfahan Cardiovascular Research Center, Isfahan UMS - Iran
Isfahan Univ Med Sci - Iran |
| 14 | Khatib, Rasha | Mujer |
Advocate Aurora Research Institute - Estados Unidos
Birzeit University - Palestina Advocate Aurora Hlth - Estados Unidos Birzeit Univ - Palestina |
| 15 | LANAS-ZANETTI, FERNANDO TOMAS | Hombre |
Universidad de La Frontera - Chile
|
| 16 | Levitt, Naomi S. | Mujer |
University of Cape Town - República de Sudáfrica
UNIV CAPE TOWN - República de Sudáfrica |
| 17 | Li, Yang | - |
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College - China
Peking Union Med Coll - China Chinese Acad Med Sci - China |
| 18 | Mohan, V. | - |
Madras Diabetes Research Foundation - India
Dr Mohans Diabet Special Ctr - India Madras Diabet Res Fdn - India |
| 19 | Mony, Prem K. | Mujer |
St. John's Medical College - India
St Johns Med Coll & Res Inst - India St. John's National Academy Of Health Sciences India - India |
| 20 | Puri, Raman | Hombre |
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval - Canadá
UNIV LAVAL - Canadá Queen's University, School of Medicine - Canadá Queens Univ - Canadá |
| 21 | Rosengren, Annika | Mujer |
Sahlgrenska Akademin - Suecia
Univ Gothenburg - Suecia Sahlgrens Univ Hosp - Suecia |
| 22 | Soman, Biju | - |
Mysore Medical College - India
Med Coll - India Sree Chitra Tirunal Inst Med Sci & Technol - India Mysore Medical College And Research Institute - India |
| 23 | Wang, Chuangshi | - |
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College - China
Peking Union Med Coll - China Chinese Acad Med Sci - China |
| 24 | Wang, Yang | - |
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College - China
Peking Union Med Coll - China Chinese Acad Med Sci - China |
| 25 | Puri, Raman | Hombre |
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval - Canadá
UNIV LAVAL - Canadá Queen's University, School of Medicine - Canadá Queens Univ - Canadá |
| 26 | Yusuf, Rita | Mujer |
Independent University, Bangladesh - Bangladesh
Independent Univ - Bangladesh |
| 27 | Yusufali, Afzal Hussein | Hombre |
Tamani Foundation - Tanzania
Tamani Fdn - Tanzania |
| 28 | Zatonska, Katarzyna | Mujer |
Wroclaw Medical University - Polonia
Wroclaw Med Univ - Polonia |
| 29 | Rangarajan, Sumathy | Mujer |
Population Health Research Institute, Ontario - Canadá
MCMASTER UNIV - Canadá |
| 30 | Yusuf, Salim | Hombre |
Population Health Research Institute, Ontario - Canadá
MCMASTER UNIV - Canadá |
| Fuente |
|---|
| Novartis |
| GlaxoSmithKline |
| Population Health Research Institute |
| Ontario Ministry of Health and Long-Term Care |
| King Pharma |
| Servier |
| Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario |
| Boehringer Ingelheim [Germany] |
| Sanofi-Aventis [Canada] |
| AstraZeneca [Canada] |
| Sanofi-Aventis [France] |
| Boehringer Ingelheim [Canada] |
| Hamilton Health Sciences Research Institute |
| Canadian Institutes of Health Research's Strategy for Patient Oriented Research through the Ontario SPOR Support Unit |
| Agradecimiento |
|---|
| The PURE study is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research's Strategy for Patient Oriented Research through the Ontario SPOR Support Unit, and the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. Further details on the funding and participating countries and institutions, and on collaborating staff, are shown in the appendix (pp 15-22). |